Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Dermatologic 1

Conditions

Pancreatic Neoplasms 2Uveal Melanoma 1Neoplasms 1Melanoma 1Histiocytic Neoplasms 1Glioma 1Gastrointestinal Neoplasms 1Colorectal Neoplasms 1

Interventions

Nivolumab 146Ipilimumab 137pembrolizumab 122Cyclophosphamide 78Interleukin-2 69aldesleukin 63Temozolomide 46trametinib 37Radiosurgery 37Vemurafenib 36fludarabine 34Biopsy 34dabrafenib 33Radiotherapy 33Blood Specimen Collection 31fludarabine phosphate 30sargramostim 27Bevacizumab 27Introns 23Dacarbazine 22Magnetic Resonance Spectroscopy 21Specimen Handling 20CTLA-4 Antigen 20encorafenib 19cobimetinib 19binimetinib 19Paclitaxel 19Granulocyte-Macrophage Colony-Stimulating Factor 19Cisplatin 17incomplete Freund's adjuvant 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Melanoma × ulixertinib × Clear all
NCT03454035 2025-09-11

Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors

UNC Lineberger Comprehensive Cancer Center

Phase 1 Recruiting
45 enrolled
DermatologicGastrointestinal

Melanoma, Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡